* EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)
LONDON, Oct 24 (Reuters) - AstraZeneca 's cancer drug pipeline received a boost on Friday as European regulators recommended approval of an experimental medicine against ovarian cancer.
LONDON/NEW YORK (Reuters) - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca .
and blood cancers. Merck's product, Keytruda (pembrolizumab) injection, is currently cleared for the treatment of melanoma. Bristol-Myers Squibb (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) are also players in the space. 1 comment!
phototherapy. Briefing docs Psoriasis-related tickers: ( JNJ -1% )( DERM -5% )( MRK -2.2% )( CELG -0.9% )( IDRA +6.8% )( HSP +1.1% )( OTC:CANF )( AMGN -1.5% )( AZN -1.1% )( PFE -1.3% ) Post your comment!
adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. OIC-related tickers: ( SLXP -0.6% )( PGNX +1.9% )( NKTR -0.5% )( AZN -2% )( CBST +0.1% )( SGYP +0.7% ) Post your comment!
* EU agency to decide on olaparib in ovarian cancer next week
Jefferies takes a bit of a different tack . It upgrades AstraZeneca ( AZN +2% ) to "Buy" based on the expectation that management ..... EPS forecast is 10% above consensus for 2015 - 2017. AZN executives would probably describe the situation differently
a lawsuit in state court accusing AstraZeneca ( AZN +2.9% ) of illegally marketing ..... that have been filed by two former AZN sales reps. The company allegedly ..... market the drug for unapproved uses. AZN settled a Justice Department suit
AstraZeneca (NYSE: AZN ) terminated its December 27, 2005 Collaborative Research and License ..... remaining rights and licenses to compounds granted by Targacept to AstraZeneca will revert back to Targacept, including compound AZD1446 (TC